Elekta to integrate cancer workflow and patient management tools into IBA's Proteus TK2 center

Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2™, a turnkey proton therapy center from Belgium-based Ion Beam Applications (IBA). The IBA proton therapy system includes a cyclotron, beam line, gantry treatment room and a fixed-beam treatment room.

IBA and Elekta announced their collaboration at the European Society of Therapeutic Radiology and Oncology (ESTRO) Anniversary Congress in London, UK, 8-12 May 2011, and the Particle Therapy Co-Operative Group (PTCOG) conference in Philadelphia, Penn., USA, 8-14 May 2011.

"IBA's Proteus TK2 is a 'no worries' approach for a cancer center's executive to successfully build a proton therapy department for their patients," says Pierre Mottet, Chief Executive Officer of IBA. "It covers everything from project planning to financing, construction, proton system installation and day-to-day operations and service. Incorporating Elekta's integrated patient management tools provides a consistently reliable diagnostic and treatment system in which clinicians and patients can completely trust."

Elekta software and devices included in the Proteus TK2 center are the MOSAIQ^® oncology information system designed specifically for oncology settings, including proton therapy clinics; auto-segmentation solutions, comprehensive treatment planning functionality that supports conventional radiation and proton-beam therapies -- including uniform scanning, scattering and spot scanning with Intensity Modulated Proton Therapy; non-invasive patient immobilization and positioning systems that provide accurate and reproducible positioning for proton therapy; and respiratory motion management to help reduce treatment margins.

"Elekta's world leading patient management solutions, which deliver oncology optimized workflow solutions will enhance the patient experience, reduce clinical risk and maximize return on investment," says Stewart Pegrum, Director Particle Therapy, Elekta. "And, clinicians know Elekta will refine its software and hardware with every advance in proton therapy technology and treatment."